ATE546430T1 - Fkbp bindende zusammensetzung und deren pharmazeutische verwendung - Google Patents

Fkbp bindende zusammensetzung und deren pharmazeutische verwendung

Info

Publication number
ATE546430T1
ATE546430T1 AT05763770T AT05763770T ATE546430T1 AT E546430 T1 ATE546430 T1 AT E546430T1 AT 05763770 T AT05763770 T AT 05763770T AT 05763770 T AT05763770 T AT 05763770T AT E546430 T1 ATE546430 T1 AT E546430T1
Authority
AT
Austria
Prior art keywords
sub
pharmaceutical use
binding composition
fkbp binding
composition
Prior art date
Application number
AT05763770T
Other languages
English (en)
Inventor
Kosley, Jr
Bruce Baron
Patrick Jimonet
John Jurcak
Stephen Shimshock
Xu-Yang Zhao
Rosy Sher
Paul Mueller
Jennifer Beall
Matthieu Barrague
Joseph Guiles
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE546430T1 publication Critical patent/ATE546430T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT05763770T 2004-06-29 2005-06-24 Fkbp bindende zusammensetzung und deren pharmazeutische verwendung ATE546430T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58374004P 2004-06-29 2004-06-29
US62494604P 2004-11-04 2004-11-04
PCT/US2005/022360 WO2006012256A2 (en) 2004-06-29 2005-06-24 Fkbp binding composition and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
ATE546430T1 true ATE546430T1 (de) 2012-03-15

Family

ID=35502420

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05763770T ATE546430T1 (de) 2004-06-29 2005-06-24 Fkbp bindende zusammensetzung und deren pharmazeutische verwendung

Country Status (7)

Country Link
EP (1) EP1778637B1 (de)
JP (1) JP4812758B2 (de)
AT (1) ATE546430T1 (de)
DK (1) DK1778637T3 (de)
ES (1) ES2383123T3 (de)
PT (1) PT1778637E (de)
WO (1) WO2006012256A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
EP4159737A1 (de) * 2020-05-28 2023-04-05 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Verfahren zur herstellung einer glp-1-rezeptoragonistfreien base
WO2023178378A1 (en) * 2022-03-21 2023-09-28 DMTC Limited Mip inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798355A (en) * 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US7056935B2 (en) 1995-06-07 2006-06-06 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5801197A (en) * 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
CA2291778A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
EP1001975A1 (de) * 1997-07-31 2000-05-24 Elan Pharmaceuticals, Inc. Benzylverbindungen, die die vla-4 vermittelte adhäsion von leukozyten inhibieren
US6268384B1 (en) 1997-08-29 2001-07-31 Vertex Pharmaceuticals Incorporated Compounds possessing neuronal activity
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US6218423B1 (en) * 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
AT500282A3 (de) * 2002-03-28 2006-06-15 Jsw Res Forschungslabor Gmbh Neurotrophe und neuroprotektive peptide

Also Published As

Publication number Publication date
ES2383123T3 (es) 2012-06-18
JP2008505077A (ja) 2008-02-21
PT1778637E (pt) 2012-05-25
JP4812758B2 (ja) 2011-11-09
WO2006012256A3 (en) 2006-04-27
EP1778637A2 (de) 2007-05-02
WO2006012256A2 (en) 2006-02-02
DK1778637T3 (da) 2012-06-18
EP1778637B1 (de) 2012-02-22

Similar Documents

Publication Publication Date Title
DE602006002700D1 (de) Tinte, Tintenset und Aufzeichnungsmethode
ATE403648T1 (de) Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung
BRPI0415288A (pt) composto, composição farmacêutica, método para tratar ou prevenir doenças, e, método para preparar o composto
CY1109722T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole
BRPI0518459A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
ATE472541T1 (de) N-(1-alkyl-2-phenylethyl)carbonsäureamidderivat und deren verwendung als fungizide
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
DE602006013115D1 (de) Benzisoxazolpiperidinverbindungen und verfahren zu deren anwendung
BRPI0508390A (pt) métodos para tratamento de dor de cáncer de osso através da administração de um antagonista de fator de crescimento de nervo
ATE530519T1 (de) Cyclobutylaminderivate
WO2008079339A3 (en) Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
BRPI0615158A8 (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição, e para preparar um composto.
TW200500339A (en) Pyrrolidine derivatives, and process for the preparation
DE602004015907D1 (de) Konjugierte Dienamide, Verfahren zur deren Herstellung, diese enthaltende Zusammensetzungen sowie deren Verwendung
DE502004002117D1 (de) Substituierte thiazol-benzoisothiazoldioxidderivative, verfahren zu deren herstellung und deren verwendung
ATE439831T1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung
ATE488510T1 (de) Heterocyclische derivate, deren herstellung und therapeutische verwendung
WO2005072408A3 (en) Treating a viral disorder
TR200100895T2 (tr) Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı
ATE546430T1 (de) Fkbp bindende zusammensetzung und deren pharmazeutische verwendung
BR0315247A (pt) Composição, composição farmacêutica, método de tratamento para uma doença proliferativa celular, e, kit
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
EA200600601A1 (ru) Производные аминопиридина в качестве ингибиторов индуцируемой no-синтазы
ATE448223T1 (de) 8-azabicycloä3.2.1üoctanderivate und ihre verwendung als monoamine-neurotransmitter- reuptake inhibitoren